US supplies most of the world’s plasma. No country depends on it more than China

A Bottle of Imported Plasma Costs a Chinese Worker Seven Months’ Pay

Healfromzero.com – In a hospital ward in Henan province, a pale-yellow fluid trickled steadily into the vein of a woman recovering from stomach-cancer surgery. Watching each drop enter her mother’s bloodstream, Ge Lan, a 44-year-old store employee from central China, described feeling the full weight of every single unit. The infusion — human albumin, the most plentiful protein found in blood plasma — was essential for rebuilding her mother’s depleted blood-protein levels after major abdominal surgery. Each 10-gram vial carried a price tag of roughly $46, making it the single most expensive item in her mother’s entire treatment regimen.

“I just hope (she) gets better soon,” Ge Lan said. “I’m worried about the money too, but I have no choice.”

Across two months of daily infusions, her mother consumed 72 vials. For Ge, whose household income came from a modest retail job, that total equated to seven months of wages. Only intervention from a sister kept the treatment from becoming financially impossible. Without those infusions, her mother’s post-surgical condition risked deteriorating sharply.

The World’s Largest Albumin Market, Fed Almost Entirely from Abroad

China consumes more human albumin than any other nation on Earth. The protein plays a critical role in managing severe trauma — including extensive burns — and in correcting chronic hypoalbuminemia linked to liver disease and other long-term conditions. Yet domestic production has long fallen far short of demand, a gap rooted in extraordinarily strict regulations governing plasma collection. Those rules trace directly back to a public-health catastrophe in the 1990s that left tens of thousands of rural residents infected with HIV.

The consequence of that historical trauma is stark: more than 60 percent of the albumin sold inside China is manufactured abroad, and every unit of that imported supply is derived from plasma collected in the United States, per a 2024 study co-authored by researchers affiliated with China’s national drug-inspection authority and its Zhejiang provincial counterpart. The United States itself accounts for approximately 70 percent of all plasma collected worldwide and stands among the very few countries that compensate donors for their contribution.

On the American Side of the Equation

For millions of Americans, donating plasma is less a civic gesture than a financial necessity. Sky Tucker, a 25-year-old community-college student, has sold plasma twice weekly for seven consecutive years to keep food on the table and care for her pets.

“While I do know it could save a life, most of the time, I’m just worried about if I’m gonna get my next meal or if I can feed my cats,” Tucker said.

That routine, repeated across thousands of US collection centers, ultimately feeds a supply chain whose downstream endpoint is often a hospital ward in Henan or another Chinese province, where a patient like Ge Lan’s mother depends on the product to survive.

A Scandal That Shaped Two Decades of Policy

The roots of China’s plasma-collection restrictions run deep into the 1990s. In the mid-1980s, Beijing had banned imports of virtually all blood products — with the sole exception of human albumin — amid escalating global anxiety over the HIV/AIDS epidemic. The government then attempted to build a domestic plasma-based industry from scratch.

In impoverished Henan, local authorities staked significant economic ambition on the plasma trade, courting hundreds of thousands of cash-strapped farmers to sell their plasma. A slogan circulated through villages across central China, captured in a 2004 report by The Beijing News, a state-run newspaper:

“Stretch your arm, show your veins; one stretch, one fist — 50 yuan earned.”

At the time, 50 yuan represented roughly a month’s earnings for many rural households. The resulting frenzy, however, was riddled with unsafe and unsanitary practices — including the reuse of needles — and ultimately fueled one of the country’s most devastating HIV outbreaks. Henan recorded its first confirmed HIV case in 1995, prompting authorities to shutter blood banks across the province. By 2004, provincial officials acknowledged that 25,000 former plasma sellers in the province had contracted the virus, a figure drawn from an official provincial census broadcast by state television.

The memory of that catastrophe hardened regulatory attitudes for decades. Plasma-collection licenses became scarce, collection volumes stayed low, and the domestic supply never recovered to meet internal demand.

Beijing’s Push to Close the Gap

Decision-makers in Beijing have grown increasingly conscious of the strategic vulnerability embedded in the current supply architecture. Xi Chen, an associate professor of public health at Yale University, noted that policymakers explicitly sought to expand domestic plasma-collection capacity.

“That’s why they wanted to enhance the capacity of collecting the plasma in the Chinese market,” Xi Chen said.

Concrete steps have followed. In 2023, dozens of newly licensed plasma-collection centers opened across the country. Last July, regulators cleared China’s first rice-derived albumin product for commercial sale — a biotechnological alternative that sidesteps the need for human plasma altogether. Both moves sit within a broader industrial strategy aimed at trimming dependence on American-sourced plasma.

Nonetheless, the arithmetic remains daunting. Industry data and domestic-demand estimates cited by Chinese state media point to an annual plasma shortfall of approximately 6,000 tons. Fully decoupling from US plasma is, by any measure, a deeply complicated undertaking for a health system still shaped by the scars of the 1990s.

What Disruption Would Mean for Patients

Researchers have cautioned that the current configuration leaves Chinese patients exposed to sudden shortages and sharp price increases should geopolitical friction or a global health emergency — the kind of shock the Covid-19 pandemic delivered — interrupt the US-dominated flow of plasma and finished albumin products. For families like Ge Lan’s, where a single course of treatment already strains household finances to the breaking point, even a modest supply disruption could translate directly into lost treatments and worsened outcomes.

The interdependence is thus asymmetric in a way that few bilateral trade relationships replicate: one side’s everyday financial survival feeds the other side’s critical-care pharmacology, and the historical wounds on the receiving end make rapid self-sufficiency both medically necessary and politically fraught.